北京商报讯（记者 丁宁）1月4日晚间，新华医疗（600587）发布公告称，公司决定使用自有资金向全 资子公司新华医疗康复产业（西安）有限公司（以下简称"西安康复公司"）增资6000万元，用于补充其 营运资金，增强其发展能力。 新华医疗表示，西安康复公司在研发、生产及销售等方面进展良好，凭借专业技术积累和精准市场定 位，已初步建立起良好的产业基础。为加快康复器械的研发、生产与销售，扩大公司规模，公司拟对西 安康复公司增资6000万元。 ...

据术锐机器人消息，2025年12月，北京术锐机器人股份有限公司完成1亿美元融资。本轮融资由正心谷 资本持续领投，上海生物医药基金持续追加，源星资本、德诺资本、合肥产投等共同参与。 ...

为保障"零关税"药械政策实施，海口海关积极研究优化通关流程，深入走访调研了解不同类型企业 享惠政策堵点痛点，研提解决措施，让政策红利精准触及享惠主体。 下一步，海口海关将继续优化监管服务，引导企业用好用足政策，进一步推动"零关税"药械政策红 利释放，助力乐城先行区打造全球优质医疗资源集聚高地。 (责任编辑：魏敏) 自2024年12月31日首票业务落地以来，海南自贸港药品、医疗器械"零关税"政策已平稳运行一周年，政 策红利持续释放。据海口海关统计，截至2025年12月31日，累计进口"零关税"药械货值约4.6亿元，减 免税款约6200万元。 海南自贸港药品、医疗器械"零关税"政策明确，在博鳌乐城国际医疗旅游先行区内注册登记具有独 立法人资格并经认定的医疗机构、医学教育高等院校、医疗类科研院所，进口政策规定范围内的药品、 医疗器械，可享受免征进口关税、进口环节增值税和消费税，降低医疗机构运营成本，更为患者就医显 著减轻负担。 ...

中新网海口1月4日电 (刘一鸣)自2024年12月31日首票业务落地以来，海南自贸港药品、医疗器械"零关 税"政策已平稳运行一周年，政策红利持续释放。据海口海关4日统计，截至2025年12月31日，累计进 口"零关税"药械货值约4.6亿元，减免税款约6200万元。 海南自贸港药品、医疗器械"零关税"政策明确，在博鳌乐城国际医疗旅游先行区内注册登记具有独立法 人资格并经认定的医疗机构、医学教育高等院校、医疗类科研院所，进口政策规定范围内的药品、医疗 器械，可享受免征进口关税、进口环节增值税和消费税，降低医疗机构运营成本，更为患者就医显著减 轻负担。 海南博鳌超级医院相关负责人冯家龙说，政策对博鳌乐城国际医疗旅游先行区内注册的医疗机构产生利 好，不仅可以减轻患者用药用械成本，也为企业资金周转提供了很大的便利。 为保障"零关税"药械政策实施，海口海关积极研究优化通关流程，深入走访调研了解不同类型企业享惠 政策堵点痛点，研提解决措施，让政策红利精准触及享惠主体。 海口海关表示，下一步将继续优化监管服务，引导企业用好用足政策，进一步推动"零关税"药械政策红 利释放，助力乐城先行区打造全球优质医疗资源集聚高地。(完) （ ...

天眼查工商信息显示，近日，济南迈瑞科技有限公司成立，法定代表人为席彬，注册资本2000万人民 币，经营范围含仪器仪表制造、第一类医疗器械生产、仪器仪表销售、货物进出口、技术进出口、进出 口代理等。股东信息显示，该公司由迈瑞医疗（300760）全资持股。 ...

Core Viewpoint - The "zero tariff" policy for drugs and medical devices in Hainan Free Trade Port has been successfully implemented for one week, significantly reducing operational costs for medical institutions and patient burdens [1]. Group 1: Policy Implementation - The "zero tariff" policy has been in effect since December 31, 2024, and has resulted in a tax reduction of approximately 62 million yuan, with a total value of goods benefiting from the policy amounting to about 460 million yuan [1]. - The policy allows registered medical institutions, higher medical education institutions, and medical research institutes in the Boao Lecheng International Medical Tourism Pilot Zone to import specified drugs and medical devices without paying import tariffs, VAT, or consumption tax [1]. Group 2: Operational Support - Haikou Customs has optimized customs clearance processes and conducted in-depth enterprise research to ensure the effective release of policy benefits, aiming to meet the needs of the beneficiaries [1]. - The customs authority will continue to enhance supervision and services, guiding enterprises to fully utilize the policy and further support the Lecheng Pilot Zone in becoming a global hub for high-quality medical resources [1]. Group 3: Policy Context - The "zero tariff" policy for drugs and medical devices is part of a broader tax incentive framework in the Hainan Free Trade Port, which also includes zero tariffs on self-use production equipment, vehicles, yachts, and raw materials [1].

其中，国际业务板块被中国家电巨头美的集团收购。根据交易条款，锐珂医疗向美的出售了其在美国以 外多个市场运营的全资企业实体的部分资产，具体交易金额未对外披露。 （锐珂医疗官方网站） 近日，美国锐珂医疗（Carestream Health, Inc.）正式宣布完成重大战略重组，公司成功分拆为两家聚焦 不同地域市场的独立企业。 ...

中国质量新闻网讯 "检查前收到责任清单，现场有人手把手指导，整改后还来复查巩固，这样的监管让 我们心里有底、经营更稳！"近日，山东省临沂市郯城县某医疗器械经营企业负责人对市场监管部门的 创新举措赞不绝口。2025年以来，郯城县市场监管局创新推行"风险预告—现场补课—回头看"三段式闭 环监管模式，实现监管与服务的同频共振。 一、事前精准预告，让企业"明方向" "进货查验记录填写不完整，按照《医疗器械经营质量管理规范》，应该这样补充……"在郯城县某医疗 器械经营企业内，执法人员一边指出问题，一边现场演示规范填写方法。这是郯城县"百问百答现场 问，药企法规送上门"活动的日常场景，执法人员化身"流动讲师"，结合检查发现的问题开展"一对 一"辅导。针对不同企业痛点，补课内容各有侧重，对新开办企业重点加强法律法规的讲解，对整改企 业手把手指导存在的问题，对偏远企业开展上门服务，确保监管无死角。推行"逢查必考"机制以来，累 计现场考核质量管理人员120余人次，开展靶向辅导20余次，帮助36家企业规范经营条件，6家企业通过 整改提升监管等级。 三、事后回头看，让整改"不打折" "上次指出的问题，现在整改到位了吗？"在助听器经 ...

为保障"零关税"药械政策实施，海口海关积极研究优化通关流程，深入走访调研了解不同类型企业享惠 政策堵点痛点，研提解决措施，让政策红利精准触及享惠主体。 自2024年12月31日首票业务落地以来，海南自贸港药品、医疗器械"零关税"政策已平稳运行一周年，政 策红利持续释放。据海口海关统计，截至2025年12月31日，累计进口"零关税"药械货值约4.6亿元，减 免税款约6200万元。 海南自贸港药品、医疗器械"零关税"政策明确，在博鳌乐城国际医疗旅游先行区内注册登记具有独立法 人资格并经认定的医疗机构、医学教育高等院校、医疗类科研院所，进口政策规定范围内的药品、医疗 器械，可享受免征进口关税、进口环节增值税和消费税，降低医疗机构运营成本，更为患者就医显著减 轻负担。 下一步，海口海关将继续优化监管服务，引导企业用好用足政策，进一步推动"零关税"药械政策红利释 放，助力乐城先行区打造全球优质医疗资源集聚高地。 （文章来源：央视新闻） ...

Investment Rating - The report maintains a "Recommended" rating for several companies in the healthcare sector, including Weili Medical, Zhend Medical, Aohua Endoscopy, and others [33]. Core Insights - The report highlights a shift in the innovative drug sector from quantity to quality, emphasizing the importance of differentiated products and internationalization for future profitability [11]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is expected to benefit from government subsidies for home medical devices [11][19]. - The life sciences service sector is showing signs of recovery, with increasing demand driven by both domestic and international markets [23]. - The pharmacy sector is poised for growth due to the acceleration of prescription outflow and an improving competitive landscape [24]. Summary by Sections Market Review - The report notes a 2.02% decline in the CITIC Medical Index, underperforming the CSI 300 Index by 1.44 percentage points, ranking 27th among 30 sectors [7]. Innovative Drugs - The innovative drug sector is expected to see a significant increase in the number of products launched, with projections of over 30 products by 2027, and a revenue share from innovative products expected to exceed 50% by 2025 [15]. Medical Devices - The report identifies a recovery in bidding for imaging devices and highlights the potential for domestic companies to increase market share through product upgrades and international expansion [19][20]. Life Sciences Services - The life sciences service sector is anticipated to benefit from a recovery in overseas demand and an increase in domestic industrial demand, with a focus on mergers and acquisitions to strengthen market positions [23]. Pharmacies - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with recommendations to focus on leading pharmacy chains [24]. Traditional Chinese Medicine - The report emphasizes the importance of basic medicines and state-owned enterprise reforms, suggesting a focus on companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical [27]. Medical Services - The report recommends focusing on companies with national expansion capabilities in the medical services sector, particularly those in traditional Chinese medicine and ophthalmology [26]. Blood Products - The blood products sector is expected to see growth due to relaxed approval processes for plasma stations and an increase in product offerings [12].